Rachel Freedman
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rachel Freedman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:55 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07123649 · Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO StudyDana-Farber Cancer Institute · recruiting · Breast Cancer · principal investigator
- N/ANCT03865654 · Individualizing Surveillance Mammography for Older Breast Cancer SurvivorsDana-Farber Cancer Institute · completed · Breast Cancer · principal investigator
- Ph1NCT03858322 · 'ADVANCE' (A Pilot Trial)Dana-Farber Cancer Institute · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT03587740 · ATOP TRIAL: T-DM1 in HER2 Positive Breast CancerDana-Farber Cancer Institute · active not recruiting · Breast Cancer · principal investigator
- N/ANCT02639208 · Novel Social Media Intervention For Older Br CA PatientsDana-Farber Cancer Institute · completed · Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III · principal investigator
- Ph2NCT01912963 · Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast CancerDana-Farber Cancer Institute · terminated · HER2-positive Breast Cancer, Metastatic Breast Cancer · principal investigator
- Ph2NCT01494662 · HKI-272 for HER2-Positive Breast Cancer and Brain MetastasesDana-Farber Cancer Institute · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Individualizing Approaches to Surveillance Mammography in Older Breast Cancer SurvivorsR01AG089237 · NIA · DANA-FARBER CANCER INST · fiscal years 2024 to 2025 · $833,902 awarded in 2025Grant number is on one of their registry trials
- Individualizing surveillance mammography for older breast cancer survivorsR21CA227615 · NCI · DANA-FARBER CANCER INST · fiscal years 2019 to 2020 · $192,487 awarded in 2020Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:55 UTC. The ranking covers the 200 most relevant of 132 PubMed records, and a shared surname and initials can bring in a namesake. All 132 on PubMed
- Ventricular pacing or dual-chamber pacing for sinus-node dysfunction.N Engl J Med · 2002734 citationsRCR 16.4
- 558 citationsRCR 13.4
- Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.Arch Gen Psychiatry · 2006441 citationsRCR 12.4
- Initial phase 2 trial of a nicotinic agonist in schizophrenia.Am J Psychiatry · 2008358 citationsRCR 10.5
- Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics.Biol Psychiatry · 1992348 citationsRCR 12.6
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.J Clin Oncol · 2019306 citationsRCR 11.1
- Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.J Clin Oncol · 1996212 citationsRCR 6.2
- Effects of nicotine on cognitive deficits in schizophrenia.Neuropsychopharmacology · 2004189 citationsRCR 5.5
- 182 citationsRCR 6.2
- Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes.Fertil Steril · 1998175 citationsRCR 6.1